{"id":"W4379282697","doi":"10.1200/jco.2023.41.16_suppl.4008","title":"Results from the pivotal phase (Ph) 2b HERIZON-BTC-01 study: Zanidatamab in previously-treated HER2-amplified biliary tract cancer (BTC).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"Medicine; Cohort; Internal medicine; Biliary tract cancer; Gemcitabine; Gallbladder cancer; Oncology; Clinical endpoint; Cancer; Metastatic breast cancer; Gastroenterology; Response Evaluation Criteria in Solid Tumors; Breast cancer; Trastuzumab; Surgery; Phases of clinical research; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003721424,0.0009543994,0.001317947,0.0002992107,0.0003079101,0.0009116399,0.0006541032,0.001020654,0.005081833],"category_scores_gemma":[0.001906355,0.0003563087,0.001373799,0.0004791748,0.0004168488,0.0005846259,0.0003644082,0.002059198,0.0009573887],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009141838,"about_ca_system_score_gemma":0.00117748,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001660436,"about_ca_topic_score_gemma":0.006620756,"domain_scores_codex":[0.9992846,0.0004101771,0.00004386215,0.00008408657,0.00008364475,0.00009372272],"domain_scores_gemma":[0.9990465,0.0002179493,0.0003141644,0.00005881004,0.00009925203,0.0002633133],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.79214,0.007374622,0.01337895,0.003937652,0.006521227,0.0002248871,0.000301479,0.003354416,0.01411163,0.0006845782,0.04482512,0.1131455],"study_design_scores_gemma":[0.8262772,0.08850477,0.05156714,0.0004629951,0.005740263,0.0005235506,0.0001187628,0.001270243,0.002190768,0.0005450917,0.0227481,0.00005116301],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8917398,0.04162982,0.00184609,0.003871171,0.0005991534,0.007623926,0.03085686,0.0002091391,0.0216241],"genre_scores_gemma":[0.9432906,0.01311385,0.002200061,0.003432397,0.0003064401,0.003335496,0.02689431,0.0001045439,0.00732231],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005081833,"threshold_uncertainty_score":0.01968104,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2021545997385521,"score_gpt":0.4946438982538278,"score_spread":0.2924892985152757,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}